Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Debt to Equity (2020 - 2023)

Historic Debt to Equity for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $0.89.

  • Candel Therapeutics' Debt to Equity rose 12998.96% to $0.89 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.89, marking a year-over-year increase of 12998.96%. This contributed to the annual value of $0.42 for FY2022, which is 474918.95% up from last year.
  • As of Q3 2023, Candel Therapeutics' Debt to Equity stood at $0.89, which was up 12998.96% from $0.66 recorded in Q2 2023.
  • Over the past 5 years, Candel Therapeutics' Debt to Equity peaked at $0.89 during Q3 2023, and registered a low of -$0.02 during Q4 2020.
  • For the 4-year period, Candel Therapeutics' Debt to Equity averaged around $0.39, with its median value being $0.39 (2022).
  • In the last 5 years, Candel Therapeutics' Debt to Equity surged by 474918.95% in 2022 and then surged by 6348.9% in 2023.
  • Over the past 4 years, Candel Therapeutics' Debt to Equity (Quarter) stood at -$0.02 in 2020, then soared by 144.43% to $0.01 in 2021, then surged by 4749.19% to $0.42 in 2022, then skyrocketed by 109.69% to $0.89 in 2023.
  • Its last three reported values are $0.89 in Q3 2023, $0.66 for Q2 2023, and $0.51 during Q1 2023.